Anti-angiogenic Effects of Thalidomide in Canine Transmissible Venereal Tumors (TVT)
World Small Animal Veterinary Association World Congress Proceedings, 2007
Estefania Flores1; Gino Cattaneo1; Carlos Gonzalez2; Raquel Cepeda3; Mariela Cabello1
1Cirugía, Depto de Cs Clínicas, 2A. Patológica, Depto de Patología and 3Histologia, Dpto de Cs biológicas, Facultad Ciencias Veterinarias y Pecuarias, Universidad de Chile
Chile

Background

The antitumoral effect of chemotherapy and radiotherapy have damaging effect not only on the neoplastic cells but also on the normal tissues. The metastasis and neoplastic growth is directly related to the capacity to generate new blood vessels for irrigation. Thalidomide is an angiogenic inhibitor and therefore it could be a potential agent for the treatment of the canine TVT (hypervascular tumor).

Aims

This study describes Thalidomide's effect on canine TVT.

Methods

Six canine patients with TVT were treated with 8mg/kg of Thalidomide orally for 7 days, followed by descending doses to day 14. Biopsies were performed at day 0 (diagnosis), day 7 and day 14. These biopsies were processed in the immunochemistry laboratory. The angiogenic activity was measured by the quantification of the vascular area in the stained plates measured in square micrometers(µ2).The morphometric computer program used was Image Pro-Plus (Media Cybernetics, USA).

Results

Table 1. Vascular area observed at day 0,7,14 in (µ2)

Patient

Day 0

Day 7

Day 14

1

4950.9546

1744.7299

517.51917

2

995.70593

548.08716

158.82558

3

1510.4462

1944.8116

115.64554

4

6920.3486

1863.1544

154.12280

5

1004.3038

930.38177

98.171059

6

4190.8149

1178.4730

42.111221

A reduction in the vascular area was observed.

Conclusion

Thalidomide as an anti-angiogenic therapy is slower than chemotherapy which kills neoplastic cells in 15 days., This is possibly due more to the neovascular blocking effect rather than antitumoral cells effect. It could be used as a complementary therapy to traditional antineoplastic therapies (surgery, chemo, radiation).

Financed by FONDECYT # 1020980

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Estefania Flores
Facultad de Cs Veterinarias y Pecuarias. Universidad de Chile.
CHILE


MAIN : Abstracts - Poster : Thalidomide & Canine TVT
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27